US Bancorp’s Faeth Therapeutics FTH Stock Holding History

US Bancorp’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5	Closed	-$1K	–	4216
2021 Q3	$1K	Buy	+5	New	+$910	﹤0.01%	4015

Other funds holding FTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

US Bancorp's FTH Position: Q4 2021 in Review

US Bancorp sold out of Faeth Therapeutics (FTH) in Q4 2021, closing a stake of 5 shares — an estimated $1K sold.

US Bancorp first reported a position in FTH in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 37 funds tracked by Wall St. Rank hold FTH as of Q4 2021.

US Bancorp reported no remaining Faeth Therapeutics position as of Q4 2021 after selling out during the quarter.
US Bancorp sold 5 Faeth Therapeutics shares in Q4 2021, an estimated $1K.
US Bancorp first reported a position in Faeth Therapeutics in Q3 2021 and held it in 1 quarter.
US Bancorp's Faeth Therapeutics position peaked at $1K in Q3 2021.
37 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q4 2021.

Based on US Bancorp's 13F filing for Q4 2021, filed 11 Feb 2022.